Document is current
Any future updates will be listed below
-
Authors
Cauvet, Anne
Decellas, Arthur
Guignabert, Christophe
Rongvaux-Gaïda, Dominique
Thuillet, Raphaël
Ottaviani, Mina
Tu, Ly
Rieger, François
Avouac, Jérôme
Allanore, Yannick
-
Funding
Funding for this research was provided by:
MEDSENIC SAS
- License Information
-
More Information
Article History
Received: 25 May 2023
Accepted: 22 August 2023
First Online: 12 September 2023
Declarations
:
: Animal experiments were carried out in accordance with the EU legislation for the protection of animals used for scientific purposes (Directive 2010/63/EU), and the study was approved by ethics committee and Ministry of Research (APAFIS#23366-2019070110126750v5).
: Not applicable.
: Y.A. received consulting honorarium from Astra-Zeneca, Bayer, Boehringer, Prometheus, Galderma, Janssen, Medsenic and Sanofi With regard to the management and treatment of systemic sclerosis. Over the last three years, C.G. reports grants from Acceleron Pharma (Cambridge, MA, USA), a wholly-owned subsidiary of Merck & Co., Inc. (Rahway, NJ, USA), MSD, Corteria, Structure therapeutics (ex ShouTi), and Janssen, outside the submitted work.
